Skip to main content

Phase 1/2 Metabolic & Obesity Deal Benchmarks

Median Upfront
$437M
Range: $222M - $648M
Total Deal Value
$2.6B
Range: $1.5B - $3.6B
Royalty Rate
12.1% - 23%
Tiered up to 27%
Dev Milestones
$512M
Range: $317M - $708M

Market Analysis

Phase 1/2 metabolic & obesity licensing deals carry a median total deal value of $2.6B, with upfront payments ranging from $222M to $648M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 17% to upfront and 83% to milestones.

The metabolic & obesity landscape at the phase 1/2 stage is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Development milestones average $512M, regulatory milestones contribute $512M, and commercial milestones reach $1.1B. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations.

Royalty rates for phase 1/2 metabolic & obesity deals range from 12.1% to 23% at the base tier, with high-tier escalation to 27%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1/2 metabolic & obesity deals?
Phase 1/2 metabolic & obesity deals average $437M in upfront payments, ranging from $222M to $648M. The upfront allocation of 17% of total deal value reflects the clinical stage risk profile.
How are phase 1/2 metabolic & obesity deal milestones structured?
Milestones account for approximately 83% of total deal value. Development milestones ($512M) represent the largest component, followed by commercial milestones ($1.1B) and regulatory milestones ($512M).
What royalty rates are typical for phase 1/2 metabolic & obesity licensing?
Base royalty rates range from 12.1% to 23%, with tiered escalation to 16.1%-27% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included